Accuray Inc. ARAY underperformed its industryin the last three months. The company’s shares have lost 22.1%, wider than the industry’s fall of 14.4%. The current return also compares unfavorably with the S&P 500 index’s rise of 0.3%. Regulatory issues regarding Onrad, intense competition in the radiation oncology market, sluggish macro economic conditions and unfavorable foreign exchange rate are significant challenges for the company.
Here's Why You Should Sell Accuray (ARAY) Stock Right Now
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться